After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Dynavax Technologies Corp. is listed on the NASDAQ in the Healthcare sector while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Dynavax Technologies Corp. is $1.50B. A total of 2.02 million shares were traded on the day, compared to an average of 1.91M shares.
In the most recent transaction, Burgess Justin sold 20,526 shares of DVAX for 12.78 per share on Mar 01 ’24. After the transaction, the Chief Accounting Officer now owns 0 company shares. In a previous transaction on Jan 04 ’24, Janssen Robert sold 1,500 shares at 15.00 per share. DVAX shares that SVP and CMO owns now total 49,925.
Among the insiders who sold shares, Novack David F disposed of 9,000 shares on Jan 02 ’24 at a per-share price of $14.45. This resulted in the President & COO holding 3,187 shares of DVAX after the transaction. In another insider transaction, Novack David F sold 20,000 shares at $13.56 per share on Dec 01 ’23. Company shares held by the President & COO now total 3,187.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, DVAX has a high of $15.15 and a low of $10.06.
As of this writing, DVAX has an earnings estimate of $Dynavax Technologies Corporatio per share for the current quarter. EPS was calculated based on a consensus of Novavax, Inc. estimates, with a high estimate of $Evaxion Biotech A/S per share and a lower estimate of $DaVita Inc..
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. DVAX’s latest balance sheet shows that the firm has $545.95M in Cash & Short Term Investments as of fiscal 2021. There were $257.38M in debt and $556.40M in liabilities at the time. Its Book Value Per Share was $4.80, while its Total Shareholder’s Equity was $222.37M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DVAX is Buy with a score of 4.60.
